Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

First Posted Date
2024-02-20
Last Posted Date
2024-07-12
Lead Sponsor
Artiva Biotherapeutics, Inc.
Target Recruit Count
51
Registration Number
NCT06265220
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

University of California, San Diego, San Diego, California, United States

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

First Posted Date
2024-02-12
Last Posted Date
2024-12-03
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
21
Registration Number
NCT06253663
Locations
πŸ‡―πŸ‡΅

Kyushu University Hospital, Fukuoka, Japan

πŸ‡―πŸ‡΅

Hokkaido University Hospital, Hokkaido, Japan

πŸ‡―πŸ‡΅

Tohoku University Hospital, Miyagi, Japan

and more 5 locations

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

First Posted Date
2024-02-12
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
210
Registration Number
NCT06253520
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

First Posted Date
2024-02-09
Last Posted Date
2024-04-16
Lead Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Target Recruit Count
112
Registration Number
NCT06251180
Locations
πŸ‡¨πŸ‡³

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

First Posted Date
2024-02-08
Last Posted Date
2024-07-23
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
40
Registration Number
NCT06249191
Locations
πŸ‡ΊπŸ‡Έ

OHSU Knight Cancer Institute, Portland, Oregon, United States

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

First Posted Date
2024-02-07
Last Posted Date
2024-05-08
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
30
Registration Number
NCT06245889
Locations
πŸ‡ΊπŸ‡Έ

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

First Posted Date
2024-02-05
Last Posted Date
2024-08-23
Lead Sponsor
Fate Therapeutics
Target Recruit Count
351
Registration Number
NCT06241456
Locations
πŸ‡ΊπŸ‡Έ

Icahn School of Medicine at Mount Sinai, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States

πŸ‡ΊπŸ‡Έ

Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States

and more 8 locations

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

First Posted Date
2024-02-02
Last Posted Date
2024-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
72
Registration Number
NCT06237881
Locations
πŸ‡ΊπŸ‡Έ

MD Anderson Cancer Center, Houston, Texas, United States

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Phase 2
Not yet recruiting
Conditions
Graft-versus-host Disease
Hematological Malignancies
Interventions
Drug: Cyclophosphamid
First Posted Date
2024-02-02
Last Posted Date
2024-02-20
Lead Sponsor
Beijing 302 Hospital
Target Recruit Count
22
Registration Number
NCT06238245

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

First Posted Date
2024-02-01
Last Posted Date
2024-12-10
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
48
Registration Number
NCT06236139
Locations
πŸ‡ΊπŸ‡Έ

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy